SCHEMBL3010342

SCHEMBL3010342

COc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3Cl)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KDM1A O60341 1/20 0.47
AR P10275 2/20 0.47
LMNA P02545 5/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 2/20 0.45
TRPV4 Q9HBA0 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007932 0.93 MAPT (0.56) MAPTUSP2RECQLHSD17B10KDM1A
SCHEMBL3002844 0.93 LMNA (0.48) MAPTUSP2RECQLHSD17B10KDM1A
SCHEMBL3019066 0.92 AR (0.54) MAPTUSP2RECQLHSD17B10KDM1A
SCHEMBL3006453 0.91 MAPT (0.47) MAPTUSP2RECQLHSD17B10KDM1A
SCHEMBL3014700 0.90 MAPT (0.52) MAPTUSP2RECQLHSD17B10KDM1A
SCHEMBL3016814 0.89 REV1 (0.53) MAPTUSP2RECQLHSD17B10AR
SCHEMBL3017059 0.89 MAPT (0.49) MAPTUSP2RECQLHSD17B10AR
SCHEMBL3016689 0.88 TP53 (0.48) MAPTUSP2RECQLHSD17B10KDM1A
SCHEMBL3020756 0.87 AR (0.49) MAPTUSP2RECQLHSD17B10AR
SCHEMBL3010513 0.87 USP2 (0.57) MAPTUSP2RECQLHSD17B10KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.